FibroBiologics Inc. has announced positive preclinical results for its investigational FSdC spheroid-based therapy, designed to treat degenerative disc disease. The data showed that FSdC spheroids led to statistically significant and superior improvements in disc preservation and structural integrity compared to other treatments in animal models. These findings support the therapy’s potential regenerative effects, including enhanced extracellular matrix remodeling and inflammation control. The results have been announced by the company but have not yet been presented at a scientific meeting. FibroBiologics plans to advance FSdC into clinical development in collaboration with regulatory authorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619739-en) on January 05, 2026, and is solely responsible for the information contained therein.